David Horn Acquires 10,000 Shares of FocalTherics (NASDAQ:FOCL) Stock

FocalTherics (NASDAQ:FOCL) Director David Horn bought 10,000 shares of FocalTherics stock in a transaction dated Friday, August 14th. The stock was acquired at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $47,500. The trade was a ? increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

FocalTherics Price Performance

Shares of NASDAQ:FOCL opened at $4.26 on Wednesday. FocalTherics has a one year low of $1.30 and a one year high of $6.40. The business’s 50 day simple moving average is $5.38. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34. The firm has a market cap of $159.66 million, a PE ratio of -4.14 and a beta of -0.04.

FocalTherics (NASDAQ:FOCL) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.The business had revenue of $13.20 million for the quarter. Equities research analysts anticipate that FocalTherics will post -0.78 earnings per share for the current year.

Hedge Funds Weigh In On FocalTherics

A number of hedge funds and other institutional investors have recently made changes to their positions in FOCL. SmartHarvest Portfolios LLC acquired a new position in shares of FocalTherics in the 1st quarter valued at $38,000. Lido Advisors LLC bought a new stake in shares of FocalTherics in the first quarter worth about $40,000. Kovack Advisors Inc. acquired a new stake in FocalTherics during the 4th quarter worth approximately $53,000. Leonteq Securities AG acquired a new stake in shares of FocalTherics during the fourth quarter worth $313,000. Finally, Flax Pond Capital LLC acquired a new stake in shares of FocalTherics in the 4th quarter valued at about $2,623,000. 62.74% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on FOCL shares. Mizuho set a $15.00 price target on FocalTherics and gave the company an “outperform” rating in a research note on Friday, July 17th. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price objective on shares of FocalTherics in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of FocalTherics in a report on Monday. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of FocalTherics in a research note on Tuesday, June 2nd. Finally, Wall Street Zen cut FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, FocalTherics currently has an average rating of “Hold” and an average target price of $7.75.

Trending Headlines about FocalTherics

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: FocalTherics insiders collectively purchased 116,000 shares for approximately $551,000 at $4.75 per share. Buyers included CEO Ryan Rhodes, CFO Kenneth Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and several directors. The coordinated open-market purchases may signal that company leadership views recent weakness as an attractive entry point. FocalTherics insider buying report
• Positive Sentiment: Director Lance Willsey made the largest purchase at 50,000 shares, while CEO Ryan Rhodes bought 21,000 shares. Other executives and directors increased their holdings by roughly 2.8% to 196%, strengthening the insider-buying signal. FocalTherics director transaction filing
• Neutral Sentiment: Recent filings show several institutional investors initiated positions, and institutions collectively own 62.74% of FocalTherics. While this indicates continued professional-investor interest, the disclosed purchases vary considerably in size and do not establish a clear near-term catalyst.
• Neutral Sentiment: A recent article characterized FocalTherics as targeting market leadership following a “record-breaking quarter,” but the available report provides insufficient financial detail to independently assess the claim. FocalTherics market leadership article
• Negative Sentiment: The company’s latest quarterly loss was $0.39 per share, substantially worse than the expected $0.20 loss, on revenue of $13.20 million. FocalTherics also reported a negative net margin of 56.26% and analysts expect a full-year loss of approximately $0.78 per share, keeping profitability and financing risk in focus.
• Negative Sentiment: Analyst opinion is mixed: although some firms maintain Buy or Outperform ratings and a $7.75 consensus target, Piper Sandler rates the stock Neutral with a $4 target, while Wall Street Zen recently downgraded it to Sell. Shares also remain below their 50-day moving average of $5.38, reflecting continued technical weakness.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.